Effect of deferasirox + erythropoietin vs erythropoietin on erythroid response in Low/Int-1-risk MDS patients: Results of the phase II KALLISTO trial.

Gattermann, Norbert; Coll, Rosa; Jacobasch, Lutz; Allameddine, Allameddine; Azmon, Amin; DeBonnett, Laurie; Bruederle, Andreas; Jin, Jie

Gattermann, Norbert; Coll, Rosa; Jacobasch, Lutz; Allameddine, Allameddine; Azmon, Amin; DeBonnett, Laurie; Bruederle, Andreas; Jin, Jie.

Afiliação

Gattermann N; Department of Hematology, Oncology and Clinical Immunology, Heinrich Heine University, Düsseldorf, Germany.
Coll R; Hospital Josep Trueta ICO Girona, Girona, Spain.
Jacobasch L; Private Practice for Hematology/Oncology, Dresden, Germany.
Allameddine A; Pennine Acute Hospital, Manchester, UK.
Azmon A; Novartis Pharma AG, Basel, Switzerland.
DeBonnett L; Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA.
Bruederle A; Novartis Pharma AG, Basel, Switzerland.
Jin J; The First Affiliated Hospital of Zhejiang University College of Medicine, Hangzhou, Zhejiang, China.

Eur J Haematol ; 2018 May 19.

Article em En | MEDLINE | ID: mdl-29777631

Palavras-chave

anemia; clinical trials; deferasirox; erythroid response; erythropoietin; hematologic response; myelodysplastic syndromes; therapy

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Clinical_trials / Etiology_studies / Risk_factors_studies Idioma: En Ano de publicação: 2018 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google